Literature DB >> 29093070

High risk of postpartum relapses in neuromyelitis optica spectrum disorder.

Eric C Klawiter1, Riley Bove2, Liene Elsone2, Enrique Alvarez2, Nadja Borisow2, Melissa Cortez2, Farrah Mateen2, Maureen A Mealy2, Jaime Sorum2, Kerry Mutch2, Sean M Tobyne2, Klemens Ruprecht2, Guy Buckle2, Michael Levy2, Dean Wingerchuk2, Friedemann Paul2, Anne H Cross2, Anu Jacobs2, Tanuja Chitnis2, Brian Weinshenker2.   

Abstract

OBJECTIVE: To study the effect of pregnancy on the frequency of neuromyelitis optica spectrum disorder (NMOSD) relapse and evaluate rates of pregnancy-related complications in an international multicenter setting.
METHODS: We administered a standardized survey to 217 women with NMOSD from 7 medical centers and reviewed their medical records. We compared the annualized relapse rate (ARR) during a baseline period 2 years prior to a participant's first pregnancy to that during pregnancy and to the 9 months postpartum. We also assessed pregnancy-related complications.
RESULTS: There were 46 informative pregnancies following symptom onset in 31 women with NMOSD. Compared to baseline (0.17), ARR was increased both during pregnancy (0.44; p = 0.035) and during the postpartum period (0.69; p = 0.009). The highest ARR occurred during the first 3 months postpartum (ARR 1.33). A total of 8 of 76 (10.5%) with onset of NMOSD prior to age 40 experienced their initial symptom during the 3 months postpartum, 2.9 times higher than expected.
CONCLUSIONS: The postpartum period is a particularly high-risk time for initial presentation of NMOSD. In contrast to published observations in multiple sclerosis, in neuromyelitis optica, relapse rate during pregnancy was also increased, although to a lesser extent than after delivery.
© 2017 American Academy of Neurology.

Entities:  

Mesh:

Substances:

Year:  2017        PMID: 29093070      PMCID: PMC5705247          DOI: 10.1212/WNL.0000000000004681

Source DB:  PubMed          Journal:  Neurology        ISSN: 0028-3878            Impact factor:   9.910


  30 in total

1.  Research electronic data capture (REDCap)--a metadata-driven methodology and workflow process for providing translational research informatics support.

Authors:  Paul A Harris; Robert Taylor; Robert Thielke; Jonathon Payne; Nathaniel Gonzalez; Jose G Conde
Journal:  J Biomed Inform       Date:  2008-09-30       Impact factor: 6.317

Review 2.  A systematic review and meta-analysis of pregnancy outcomes in patients with systemic lupus erythematosus and lupus nephritis.

Authors:  Andrew Smyth; Guilherme H M Oliveira; Brian D Lahr; Kent R Bailey; Suzanne M Norby; Vesna D Garovic
Journal:  Clin J Am Soc Nephrol       Date:  2010-08-05       Impact factor: 8.237

Review 3.  Pregnancy-induced up-regulation of aquaporin-4 protein in brain and its role in eclampsia.

Authors:  Allison M Quick; Marilyn J Cipolla
Journal:  FASEB J       Date:  2005-02       Impact factor: 5.191

4.  Revised diagnostic criteria for neuromyelitis optica.

Authors:  D M Wingerchuk; V A Lennon; S J Pittock; C F Lucchinetti; B G Weinshenker
Journal:  Neurology       Date:  2006-05-23       Impact factor: 9.910

Review 5.  Epidemiology of pre-eclampsia and the other hypertensive disorders of pregnancy.

Authors:  Jennifer A Hutcheon; Sarka Lisonkova; K S Joseph
Journal:  Best Pract Res Clin Obstet Gynaecol       Date:  2011-02-18       Impact factor: 5.237

6.  Exclusive Breastfeeding and the Effect on Postpartum Multiple Sclerosis Relapses.

Authors:  Kerstin Hellwig; Milena Rockhoff; Sandra Herbstritt; Nadja Borisow; Aiden Haghikia; Birte Elias-Hamp; Sylvia Menck; Ralf Gold; Annette Langer-Gould
Journal:  JAMA Neurol       Date:  2015-10       Impact factor: 18.302

7.  Rate of pregnancy-related relapse in multiple sclerosis. Pregnancy in Multiple Sclerosis Group.

Authors:  C Confavreux; M Hutchinson; M M Hours; P Cortinovis-Tourniaire; T Moreau
Journal:  N Engl J Med       Date:  1998-07-30       Impact factor: 91.245

8.  IgG marker of optic-spinal multiple sclerosis binds to the aquaporin-4 water channel.

Authors:  Vanda A Lennon; Thomas J Kryzer; Sean J Pittock; A S Verkman; Shannon R Hinson
Journal:  J Exp Med       Date:  2005-08-08       Impact factor: 14.307

9.  International consensus diagnostic criteria for neuromyelitis optica spectrum disorders.

Authors:  Dean M Wingerchuk; Brenda Banwell; Jeffrey L Bennett; Philippe Cabre; William Carroll; Tanuja Chitnis; Jérôme de Seze; Kazuo Fujihara; Benjamin Greenberg; Anu Jacob; Sven Jarius; Marco Lana-Peixoto; Michael Levy; Jack H Simon; Silvia Tenembaum; Anthony L Traboulsee; Patrick Waters; Kay E Wellik; Brian G Weinshenker
Journal:  Neurology       Date:  2015-06-19       Impact factor: 9.910

10.  Female hormonal exposures and neuromyelitis optica symptom onset in a multicenter study.

Authors:  Riley Bove; Liene Elsone; Enrique Alvarez; Nadja Borisow; Melissa M Cortez; Farrah J Mateen; Maureen A Mealy; Kerry Mutch; Sean Tobyne; Klemens Ruprecht; Guy Buckle; Michael Levy; Dean M Wingerchuk; Friedemann Paul; Anne H Cross; Brian Weinshenker; Anu Jacob; Eric C Klawiter; Tanuja Chitnis
Journal:  Neurol Neuroimmunol Neuroinflamm       Date:  2017-03-24
View more
  12 in total

1.  Impact of comorbid Sjögren syndrome in anti-aquaporin-4 antibody-positive neuromyelitis optica spectrum disorders.

Authors:  Tetsuya Akaishi; Toshiyuki Takahashi; Kazuo Fujihara; Tatsuro Misu; Juichi Fujimori; Yoshiki Takai; Shuhei Nishiyama; Michiaki Abe; Tadashi Ishii; Masashi Aoki; Ichiro Nakashima
Journal:  J Neurol       Date:  2021-01-08       Impact factor: 4.849

Review 2.  Neuromyelitis optica spectrum disorders and pregnancy: relapse-preventive measures and personalized treatment strategies.

Authors:  Nadja Borisow; Kerstin Hellwig; Friedemann Paul
Journal:  EPMA J       Date:  2018-08-10       Impact factor: 6.543

Review 3.  [Neuromyelitis optica spectrum disorder and pregnancy].

Authors:  N Borisow; K Hellwig; F Paul
Journal:  Nervenarzt       Date:  2018-06       Impact factor: 1.214

Review 4.  Neuromyelitis optica spectrum disorders and pregnancy: therapeutic considerations.

Authors:  Yang Mao-Draayer; Sandra Thiel; Elizabeth A Mills; Tanuja Chitnis; Michelle Fabian; Ilana Katz Sand; M Isabel Leite; Sven Jarius; Kerstin Hellwig
Journal:  Nat Rev Neurol       Date:  2020-02-20       Impact factor: 42.937

5.  Inflammatory and anti-inflammatory markers in plasma: from late pregnancy to early postpartum.

Authors:  Emma Bränn; Åsa Edvinsson; Anna Rostedt Punga; Inger Sundström-Poromaa; Alkistis Skalkidou
Journal:  Sci Rep       Date:  2019-02-12       Impact factor: 4.379

Review 6.  New Therapeutic Landscape in Neuromyelitis Optica.

Authors:  Madina Tugizova; Luka Vlahovic; Anna Tomczak; Nora Sandrine Wetzel; May Htwe Han
Journal:  Curr Treat Options Neurol       Date:  2021-03-30       Impact factor: 3.972

7.  Pregnancy outcome in patients with neuromyelitis optica spectrum disorder treated with rituximab: A case-series study.

Authors:  Maral Seyed Ahadi; Mohammad Ali Sahraian; Vahid Shaygannejad; Nassim Anjidani; Seyed Ehsan Mohammadiani Nejad; Nahid Beladi Moghadam; Hormoz Ayromlou; Gholam Ali Yousefi Pour; Sepideh Yazdanbakhsh; Mehrdad Jafari; Abdorreza Naser Moghadasi
Journal:  Caspian J Intern Med       Date:  2021

8.  Pregnancy and Neuromyelitis Optica Spectrum Disorder - Reciprocal Effects and Practical Recommendations: A Systematic Review.

Authors:  Rohan D'Souza; Danielle Wuebbolt; Katarina Andrejevic; Rizwana Ashraf; Vanessa Nguyen; Nusrat Zaffar; Dalia Rotstein; Ahraaz Wyne
Journal:  Front Neurol       Date:  2020-10-16       Impact factor: 4.003

9.  Neuromyelitis optica spectrum disorder: pregnancy-related attack and predictive risk factors.

Authors:  Liang Wang; Lei Zhou; Jingzi ZhangBao; Wenjuan Huang; Xuechun Chang; Chuanzhen Lu; Min Wang; Wenyu Li; Junhui Xia; Xiang Li; Lilin Chen; Wei Qiu; Jiahong Lu; Chongbo Zhao; Chao Quan
Journal:  J Neurol Neurosurg Psychiatry       Date:  2020-11-20       Impact factor: 10.154

Review 10.  Recent progress in maintenance treatment of neuromyelitis optica spectrum disorder.

Authors:  Trygve Holmøy; Rune Alexander Høglund; Zsolt Illes; Kjell-Morten Myhr; Øivind Torkildsen
Journal:  J Neurol       Date:  2020-10-03       Impact factor: 6.682

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.